2,052
Participants
Start Date
November 30, 2014
Primary Completion Date
January 12, 2018
Study Completion Date
January 12, 2018
Immediate Genetic Testing
Participants will receive the APOL1 genetic test. Trained research staff will meet with participants to communicate results and lifetime ESRD risk attributable to variations in the APOL1 gene. Primary care providers will receive APOL1 genetic risk information via a best practice alert in the participant's EMR upon commencement of a patient encounter and through results filed in the participant's genetics results section of their EMR.
Institute for Family Health, New York
Icahn School of Medicine at Mount Sinai, New York
Icahn School of Medicine at Mount Sinai
OTHER